- $93.95m
- $135.95m
- $78.23m
- 16
- 53
- 21
- 20
Annual income statement for OptiNose, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 49.1 | 74.7 | 76.3 | 71 | 78.2 |
| Cost of Revenue | |||||
| Gross Profit | 41.6 | 65.5 | 67 | 62.4 | 71 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 136 | 141 | 132 | 93.7 | 94.5 |
| Operating Profit | -87.2 | -66.5 | -55.9 | -22.7 | -16.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -99.8 | -82.3 | -74.8 | -35.5 | -21.5 |
| Net Income After Taxes | -99.8 | -82.3 | -74.8 | -35.5 | -21.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -99.8 | -82.3 | -74.8 | -35.5 | -21.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -99.8 | -82.3 | -74.8 | -35.5 | -21.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -31 | -21.7 | -13.1 | -4.75 | -2.12 |